Ubs Group Ag Mannkind Corp Transaction History

Ubs Group Ag

$527 Billion
Q4 2024

A detailed history of Ubs Group Ag transactions in Mannkind Corp stock. As of the latest transaction made, Ubs Group Ag holds 3,300,209 shares of MNKD stock, worth $19 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

3,300,209

Previous 653,489 405.01%

Holding current value

$19 Million

Previous $4.1 Million 417.18%

% of portfolio

0.0%

Previous 0.0%

32 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Feb 14, 2025	BUY	$5.93 - $7.44 $15.7 Million - $19.7 Million	2,646,720 Added 405.01%	3,300,209 $21.2 Million
Q3 2024 Nov 14, 2024	BUY	$5.01 - $6.7 $894,360 - $1.2 Million	178,515 Added 37.58%	653,489 $4.1 Million
Q2 2024 Aug 13, 2024	SELL	$4.05 - $5.43 $831,841 - $1.12 Million	-205,393 Reduced 30.19%	474,974 $2.48 Million
Q1 2024 May 13, 2024	SELL	$3.25 - $5.27 $120,627 - $195,601	-37,116 Reduced 5.17%	680,367 $3.08 Million
Q4 2023 Feb 09, 2024	BUY	$3.34 - $4.29 $1.29 Million - $1.66 Million	386,868 Added 117.01%	717,483 $2.61 Million
Q3 2023 Nov 09, 2023	SELL	$3.91 - $5.45 $399,723 - $557,158	-102,231 Reduced 23.62%	330,615 $1.37 Million
Q2 2023 Aug 11, 2023	SELL	$3.72 - $4.79 $382,140 - $492,057	-102,726 Reduced 19.18%	432,846 $1.76 Million
Q1 2023 May 12, 2023	SELL	$3.95 - $5.63 $1.44 Million - $2.06 Million	-365,822 Reduced 40.58%	535,572 $2.2 Million
Q4 2022 Feb 08, 2023	BUY	$3.02 - $5.37 $2.04 Million - $3.62 Million	674,505 Added 297.28%	901,394 $4.75 Million
Q3 2022 Nov 10, 2022	SELL	$2.99 - $4.35 $26,021 - $37,858	-8,703 Reduced 3.69%	226,889 $701,000
Q2 2022 Aug 10, 2022	SELL	$2.67 - $4.77 $1.68 Million - $2.99 Million	-627,515 Reduced 72.7%	235,592 $897,000
Q1 2022 May 16, 2022	BUY	$2.62 - $4.45 $321,895 - $546,731	122,861 Added 16.6%	863,107 $3.18 Million
Q4 2021 Feb 14, 2022	BUY	$4.05 - $5.37 $874,119 - $1.16 Million	215,832 Added 41.16%	740,246 $3.24 Million
Q3 2021 Nov 15, 2021	BUY	$3.89 - $5.48 $1.64 Million - $2.3 Million	420,611 Added 405.2%	524,414 $2.28 Million
Q2 2021 Aug 13, 2021	SELL	$3.61 - $5.45 $1.1 Million - $1.65 Million	-303,468 Reduced 74.51%	103,803 $566,000
Q1 2021 May 12, 2021	BUY	$3.14 - $6.14 $1.19 Million - $2.33 Million	379,150 Added 1348.28%	407,271 $1.6 Million
Q4 2020 Feb 11, 2021	BUY	$1.79 - $4.04 $302 - $682	169 Added 0.6%	28,121 $88,000
Q3 2020 Nov 12, 2020	SELL	$1.56 - $2.08 $10,849 - $14,466	-6,955 Reduced 19.92%	27,952 $52,000
Q2 2020 Jul 31, 2020	BUY	$0.94 - $2.21 $5,110 - $12,015	5,437 Added 18.45%	34,907 $61,000
Q1 2020 May 01, 2020	BUY	$0.84 - $1.76 $9,657 - $20,234	11,497 Added 63.97%	29,470 $31,000
Q4 2019 Feb 14, 2020	BUY	$1.14 - $1.49 $15,959 - $20,860	14,000 Added 352.38%	17,973 $23,000
Q3 2019 Nov 14, 2019	SELL	$1.04 - $1.44 $13,996 - $19,379	-13,458 Reduced 77.21%	3,973 $5,000
Q2 2019 Aug 14, 2019	SELL	$1.09 - $1.88 $23,872 - $41,173	-21,901 Reduced 55.68%	17,431 $20,000
Q1 2019 May 14, 2019	BUY	$1.14 - $2.25 $24,531 - $48,417	21,519 Added 120.81%	39,332 $77,000
Q4 2018 Feb 14, 2019	SELL	$1.02 - $2.05 $122 - $245	-120 Reduced 0.67%	17,813 $19,000
Q3 2018 Nov 14, 2018	BUY	$1.01 - $2.19 $8,847 - $19,184	8,760 Added 95.5%	17,933 $33,000
Q2 2018 Aug 14, 2018	SELL	$1.59 - $2.38 $8,268 - $12,376	-5,200 Reduced 36.18%	9,173 $17,000
Q1 2018 May 15, 2018	SELL	$2.28 - $3.8 $27,670 - $46,116	-12,136 Reduced 45.78%	14,373 $33,000
Q4 2017 Feb 14, 2018	BUY	$2.28 - $6.71 $27,008 - $79,486	11,846 Added 80.79%	26,509 $61,000
Q3 2017 Nov 14, 2017	SELL	$1.15 - $2.29 $114,175 - $227,358	-99,283 Reduced 87.13%	14,663 $32,000
Q2 2017 Aug 14, 2017	BUY	N/A	82,637 Added 263.94%	113,946 $160,000
Q1 2017 Nov 14, 2017	BUY	N/A	31,309	31,309 $47,000

Others Institutions Holding MNKD

# of Institutions

260

Shares Held

161M

Call Options Held

1.97M

Put Options Held

943K

View Full List

About MANNKIND CORP

Ticker MNKD
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 257,338,000
Market Cap $1.48B
Description
MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes. It also promotes Thyquidity to adult and pediatric endocri...

More about MNKD

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Group Ag, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Group Ag with notifications on news.

Account